1. Home
  2. TARS vs VERA Comparison

TARS vs VERA Comparison

Compare TARS & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$61.92

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$43.01

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
VERA
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.5B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
TARS
VERA
Price
$61.92
$43.01
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$89.00
$81.30
AVG Volume (30 Days)
529.2K
1.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
48.21
N/A
EPS
N/A
N/A
Revenue
$451,360,000.00
N/A
Revenue This Year
$56.43
N/A
Revenue Next Year
$30.19
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
146.71
N/A
52 Week Low
$38.51
$19.07
52 Week High
$85.25
$56.05

Technical Indicators

Market Signals
Indicator
TARS
VERA
Relative Strength Index (RSI) 47.11 74.10
Support Level $60.95 $37.54
Resistance Level $66.36 $47.00
Average True Range (ATR) 2.83 1.94
MACD 0.40 1.16
Stochastic Oscillator 28.21 99.04

Price Performance

Historical Comparison
TARS
VERA

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: